Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Non-Viral Gene Delivery Technologies Market Growth From $5.28 Billion In 2026 To $9.26 Billion By 2030 At A CAGR Of 15.1%
The market size for non-viral gene delivery technologies has expanded rapidly in recent years. It will grow from $4.57 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The historical growth of this market can be attributed to factors such as reliance on viral delivery methods, limited availability of non-viral transfection reagents, increasing interest in gene therapy research, growing use of plasmid dna and mrna delivery kits, and the adoption of electroporation and physical delivery techniques.
The non-viral gene delivery technologies market is anticipated to undergo significant expansion over the next few years. It is projected to attain a value of $9.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.1%. This expected growth throughout the forecast period can be attributed to several factors, including the advancement of lipid and polymer nanoparticles, the proliferation of pre-formulated nanoparticle technologies, increased investment in gene editing and RNAi therapeutics, a growing demand for personalized gene therapy solutions, and the integration of high-throughput and automated delivery platforms. Key trends foreseen during this period encompass the rising adoption of lipid-based and polymer-based non-viral delivery systems, an expansion in CRISPR and Cas9 gene editing applications, heightened demand for RNAi and DNA vaccine delivery platforms, the growth of ex-vivo and in-vivo gene therapy research, and the development of cell-specific and targeted gene delivery reagents.
Get A Free Sample Report With In-Depth Market Insights:
Non-Viral Gene Delivery Technologies Market Growth Factors: What’s Supporting Expansion?
The market for non-viral gene delivery technologies is anticipated to grow due to the rising demand for personalized medicine. This medical strategy involves tailoring prevention, diagnosis, and treatment according to an individual’s distinct genetic profile, lifestyle, and environmental factors. The growing need for personalized medicine stems from progress in genomic sequencing technologies, which enable more precise diagnoses, specific therapies, and better patient outcomes customized for each person. This increasing emphasis on personalized medicine is boosting the need for non-viral gene delivery technologies because they provide safer and more flexible ways to administer therapeutic genes aligned with a person’s genetic makeup, without the dangers linked to viral vectors. For example, data from February 2024, provided by the US-based non-profit organization, the Personalized Medicine Coalition, indicates that the Food and Drug Administration (FDA) sanctioned 16 new personalized therapies for individuals with rare diseases in 2023, an increase from 6 in 2022. Consequently, the rising demand for personalized medicine is fueling the expansion of the non-viral gene delivery technologies market.
Non-Viral Gene Delivery Technologies Market Segment Landscape: Which Areas Lead Development?
The non-viral gene delivery technologies market covered in this report is segmented –
1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles
2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo
3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles
4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
Subsegments:
1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents
2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems
3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles
Non-Viral Gene Delivery Technologies Market Industry Trends: What’s Reshaping Demand?
Companies operating in the non-viral gene delivery market are concentrating on developing advanced solutions, such as non-viral genetic medicine platforms, to enhance the safety and efficiency of gene therapies. A non-viral genetic medicine platform utilizes technology to introduce therapeutic genes or nucleic acids into cells without viruses, thereby reducing immune reactions and safety concerns, and facilitating precise and controlled gene therapy delivery for various diseases. For example, in October 2023, Generation Bio Co., a US-based biotechnology company focused on genetic medicines, introduced immune-quiet DNA (iqDNA). This novel DNA is an optimized version of their closed-ended DNA (ceDNA) designed to evade innate immune detection, exhibiting cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered through their lipid nanoparticle (LNP) system. Given iqDNA’s superior tolerability, Generation Bio is progressing this as the primary DNA cargo across all its programs, including its leading hemophilia A program.
Non-Viral Gene Delivery Technologies Market Industry Leaders And Competitive Landscape
Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.
View The Full Non-Viral Gene Delivery Technologies Market Report:
Non-Viral Gene Delivery Technologies Market Top Region By Revenue And Market Share
North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
